MedTrace Logo

Arsenous Acid for Refractory Triple-Negative Breast Cancer

NCT06678048 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-06-06

No results posted yet for this study

Summary

The primary objective of this study is to assess the progression-free survival (PFS) and safety of arsenous acid in combination with palliative chemotherapy for refractory triple-negative breast cancer following multiple lines of treatment.

Conditions

Interventions

DRUG

Arsenous Acid plus Chemotherapy

Arsenous Acid , Eribulin, Gemcitabine, Utidelone, Vinorelbine

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-23
Primary Completion
2026-04-22
Completion
2026-10-23

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06678048 on ClinicalTrials.gov